VICRYL RAPIDE SUTURE

K944110 · ETHICON, Inc. · GAM · Jan 18, 1995 · General, Plastic Surgery

Device Facts

Record IDK944110
Device NameVICRYL RAPIDE SUTURE
ApplicantETHICON, Inc.
Product CodeGAM · General, Plastic Surgery
Decision DateJan 18, 1995
DecisionSN
Submission TypeTraditional
Regulation21 CFR 878.4493
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The Vicryl™ Rapide Suture is indicated only for use in superficial soft tissue approximation of skin and mucosa where only short-term wound support (7-10 days) is required. Vicryl™ Rapide Suture is not intended for use in ligation, ophthalmic, cardiovascular or neurological procedures.

Device Story

VICRYL Rapide is a sterile, flexible, braided, multifilament synthetic absorbable suture; composed of a copolymer of glycolide and lactide; coated with a mixture of glycolide/L-lactide copolymer and calcium stearate. Used by clinicians for superficial soft tissue approximation (skin and mucosa) where rapid absorption is beneficial and short-term support (7-10 days) is sufficient. Eliminates need for suture removal in many cases. Provides favorable cosmetic results. Sterilized via Cobalt-60 irradiation.

Clinical Evidence

Clinical study conducted by ETHICON GmbH & Co KG evaluated surgical performance in episiotomies, cutaneous skin closure, and circumcisions. Results indicated good overall performance, favorable cosmetic outcomes, and reduced need for suture removal.

Technological Characteristics

Multifilament braided synthetic absorbable suture. Materials: copolymer of glycolide and lactide; coating of glycolide/L-lactide copolymer and calcium stearate. Sterilization: Cobalt-60 irradiation (SAL 10^-6). Packaging: paper folder in sealed foil package with overwrap.

Indications for Use

Indicated for superficial soft tissue approximation of skin and mucosa requiring short-term wound support (7-10 days). Contraindicated for ligation, ophthalmic, cardiovascular, or neurological procedures.

Regulatory Classification

Identification

An absorbable poly(glycolide/l-lactide) surgical suture (PGL suture) is an absorbable sterile, flexible strand as prepared and synthesized from homopolymers of glycolide and copolymers made from 90 percent glycolide and 10 percent l-lactide, and is indicated for use in soft tissue approximation. A PGL suture meets United States Pharmacopeia (U.S.P.) requirements as described in the U.S.P. “Monograph for Absorbable Surgical Sutures;” it may be monofilament or multifilament (braided) in form; it may be uncoated or coated; and it may be undyed or dyed with an FDA-approved color additive. Also, the suture may be provided with or without a standard needle attached.

Special Controls

*Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.

Predicate Devices

Submission Summary (Full Text)

{0} [LOGO] DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JAN 18 1995 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20856 John D. Paulson, Ph.D. Director, Regulatory Affairs Ethicon, Inc. P.O. Box 151 Somerville, New Jersey 08876-0151 Re: K944110 VICRYL™ Rapide Suture Regulatory Class: II Dated: November 29, 1994 Received: November 30, 1994 Dear Dr. Paulson: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices that were regulated as transitional devices and that have been reclassified into class II. Notice of this reclassification was published in the Federal Register on Wednesday, September 18, 1991 (Vol. 56, No. 18, Pages 47150 and 47151). A copy of this Federal Register can be obtained by calling the Division of Small Manufacturers Assistance (DSMA) at (800) 638-2041 or (301) 443-6597. You may, therefore, market the device, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) and the following limitations: 1. The Vicryl™ Rapide Suture is indicated only for use in superficial soft tissue approximation of skin and mucosa where only short-term wound support (7-10 days) is required. Vicryl™ Rapide Suture is not intended for use in ligation, ophthalmic, cardiovascular or neurological procedures. 2. This device may not be manufactured from any material other than homopolymers and copolymers made from glycolide and/or L-lactide. Any deviation of the polymer composition or processing as described in this 510(k) notification must be submitted to FDA in a new premarket notification at least 90 days prior to implementation of the proposed changes. In addition, you must maintain documentation at your premises regarding vendor {1} Page 2 - John D. Paulson, Ph.D. certification for raw or semiprocessed source material, all manufacturing and quality control release procedures, and validation of sterilization procedures used in the manufacture of the Vicryl™ Rapide surgical suture. Any deviation of the source material or processing as described in this 510(k) notification requires submission of a new premarket notification and Food and Drug Administration (FDA) clearance prior to commercial distribution of the modified device. The sale, distribution and use of this device are restricted to prescription use in accordance with 21 CFR 801.109. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practices, labeling, and prohibition against misbranding and adulteration. Existing major regulations affecting your device can be found in the Code of Federal Regulations (CFR), Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practices (GMP) for Medical Devices: General GMP regulation (21 CFR Part 820) and that, through periodic GMP inspections, The Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control Provisions, or other Federal laws or regulations. This letter immediately will allow you to begin marketing your device as described in your 510(k) premarket notification. An FDA finding of substantial equivalence of your device to a reclassified transitional device results in a classification for your device and permits your device to proceed to the market, but it does not mean that FDA approves your device. Therefore, you may not promote or in any way represent your device or its labeling as being approved by FDA. If you desire specific advice regarding labeling for your device in accordance with 21 CFR Part 801, promotion, or advertising please contact the Office of Compliance, Promotion and Advertising Policy Staff (HFZ-302) at (301) 594-4639. Other 2 {2} Page 3 - John D. Paulson, Ph.D. general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at their toll free number (800) 638-2041 or at (301) 443-6597. Sincerely yours, Ann C. Forrester Paul R. Beninger, M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health 3 {3} ### 510(k) SUMMARY SUBSTANTIAL EQUIVALENCE OF VICRYL* RAPIDE (POLYGLACTIN 910) BRAIDED COATED SYNTHETIC ABSORBABLE SUTURE, UNDYED TO COATED VICRYL* (POLYGLACTIN 910) SYNTHETIC ABSORBABLE SUTURE This 510(k) Summary demonstrates that VICRYL rapide suture is substantially equivalent in design and composition to the currently marketed Coated VICRYL suture. VICRYL rapide suture is also substantially equivalent to currently marketed ETHICON* surgical gut (plain) suture in surgical performance. NEW DEVICE: VICRYL rapide Braided Coated Synthetic Absorbable Suture, undyed VICRYL rapide suture, undyed is a sterile suture, flexible multifilament strand prepared from a copolymer made from glycolide and lactide. The coating for VICRYL rapide suture is prepared with a mixture of a copolymer of glycolide and L-lactide and calcium stearate. VICRYL rapide suture is intended for use in soft tissue approximation, (i.e., mucosa and skin), where only short term wound support is required and where the rapid absorption of the suture would be beneficial. ETHICON GmbH & Co KG, Germany has conducted a clinical study to demonstrate the surgical performance of VICRYL rapide suture. The evaluations were conducted in a variety of surgical procedures that included episiotomies, cutaneous skin closure and circumcisions. In this study, overall performance was good for VICRYL rapide suture with special emphasis on favorable cosmetic results and the fact that suture removal is often not required. VICRYL rapide suture is made from the same copolymer composition as the predicate device. VICRYL rapide suture was evaluated in a variety of biocompatibility studies. The results of these studies did not raise any new safety and effectiveness concerns. VICRYL rapide suture will be sterilized by Cobalt-60 irradiation to a minimum Sterility Assurance Level (SAL) of 10⁶. The packaging consists of an inner paper folder placed within a sealed labeled foil package. This package is then enveloped in an overwrap pouch. Secondary packaging consisting of sales cartons and corrugated shipping containers will be used to protect the product and package during storage and distribution. PREDICATE DEVICE: Coated VICRYL suture is a sterile, synthetic absorbable suture intended for clinical use in soft tissue approximation and/or ligation including ophthalmic surgery. ETHICON* surgical (plain) gut suture is intended for use in soft tissue approximation and/or ligation including ophthalmic surgery. Except for clinical use in ligation and ophthalmic surgery, and use of VICRYL rapide suture where only short term wound support is required, VICRYL rapide suture and Coated VICRYL suture both have the same clinical use in that they are intended for use in all types of soft tissue approximation. Both VICRYL rapide sutures and Coated VICRYL sutures are fabricated from the same copolymer of glycolide and L-lactide and coating that consists of a copolymer of glycolide, lactide and calcium stearate. Both VICRYL rapide suture and Coated VICRYL suture use the same component materials that are recognized as being safe as surgical implant materials. Based on the information in this summary, it can be concluded that within its indications for use, VICRYL rapide suture is substantially equivalent in surgical performance to ETHICON surgical (plain) gut suture and in design and composition to Coated VICRYL suture. * Trademark 126 59
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...